Prostanorm

Quick links to important sections

Prostanorm

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostanorm

Quick Facts

Property Description
Active ingredient Terazosin Hydrochloride
Form Oral capsule or tablet
Pharmacological class Alpha-blocker (Selective alpha1-adrenergic antagonist)
General purpose Smooth muscle relaxation; reduction of internal resistance
Origin Synthetic quinazoline derivative

Prostanorm is a prescription-only medicine containing the active ingredient Terazosin, and it is classified as an alpha-blocker. This type of medication works by relaxing certain smooth muscles in the body to improve flow, addressing reduced pressure in the lower urinary tract and blood vessels.


What Type of Medicine is Prostanorm?

Prostanorm is an oral, single-ingredient product whose active component is Terazosin Hydrochloride. It is categorized as an alpha-blocker, or selective alpha1-adrenergic antagonist, which represents a class of synthetic drugs developed to modulate the autonomic nervous system. This classification is clinically recognized for addressing conditions where smooth muscle constriction contributes to physiological resistance. As a quinazoline derivative, Terazosin's specific molecular structure provides a highly targeted mechanism compared to less selective agents.


Prostanorm’s Composition and Form

The core of Prostanorm is the single active ingredient, Terazosin, which is supplied for oral administration in the form of a capsule or tablet. Its composition is strictly defined, consisting only of the active Terazosin Hydrochloride combined with the necessary inert excipient base to create the solid oral dosage unit. Being a single-ingredient product, its pharmacological effect is solely derived from the action of the alpha-blocker. This formulation is typically utilized for adult male patients experiencing symptoms where pressure relief is required in the urinary system.


What is the General Physiological Purpose of an Alpha-Blocker?

The general physiological purpose of an alpha-blocker like Prostanorm is to induce smooth muscle relaxation in targeted areas. It works by blocking alpha1-adrenergic receptors, thereby inhibiting nerve signals that cause these muscles to contract. This mechanism achieves the general benefit of reducing internal resistance: by easing tension in the smooth muscle around the bladder neck and prostate, and by relaxing the walls of blood vessels, it facilitates better flow through both the urinary and circulatory systems.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Prostanorm?

Possible Side Effects and Safety Information

The safety profile of Prostanorm (Terazosin) is officially documented by regulatory agencies, with adverse reactions frequently classified by their observed incidence in clinical use. The most commonly reported events are related to the drug's effect on the vascular and nervous systems, which can manifest as symptomatic hypotension.


Officially Documented Adverse Reactions

Classification Example Adverse Reactions (SOC)
Very Common (\ge1/10) Dizziness (Nervous System), Asthenia (General Disorders)
Common (1/100 to 1/10) Postural hypotension (Vascular), Somnolence (Nervous System), Impotence (Reproductive System)
Not Known (Postmarketing) Priapism (Reproductive System), Anaphylaxis (Immune System)

Regulatory Safety Considerations

Certain clinically significant events are specifically noted in official prescribing information. Syncope (fainting) is documented as a serious risk, with the highest incidence occurring during the initial period of treatment or following a dose increase. This pattern is often referred to as a "first-dose" effect.

Specific patient populations have additional documented safety considerations. Older adults (age 65 and over) have an increased recorded incidence of postural hypotensive events compared to younger patients. Additionally, patients undergoing cataract surgery must inform their surgeon of current or past use, due to the documented risk of Intraoperative Floppy Iris Syndrome (IFIS).

High-level safety restrictions include a contraindication for individuals with known hypersensitivity to Terazosin or quinazoline derivatives. Furthermore, co-administration with other antihypertensive agents can result in additive blood pressure lowering effects, a safety consequence noted in regulatory warnings.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Prostanorm (Terazosin Hydrochloride) defines overdose based on the profound physiological effect of excessive alpha-blockade, primarily a severe and sustained reduction of blood pressure (hypotension). Clinical manifestations explicitly documented in regulatory sources include episodes of extreme dizziness and the potential for syncope (fainting), which is a serious, sudden outcome of severe hypotension.

Due to the risk that severe hypotension may progress to a state of shock, official labeling mandates that individuals seek immediate medical attention for any suspected overdose. Regulatory documents specify contacting a regional Poison Control Centre as a required emergency action when overdose is confirmed or suspected.

The officially documented management procedures are strictly symptomatic and supportive, as no specific antidote is described in regulatory information. Treatment focuses on restoring hemodynamic stability, which includes placing the patient in a supine position with elevated lower extremities to encourage blood pressure recovery. For persistent hypotension or shock, the regulatory documents describe the necessity of administering volume expanders. The potential subsequent use of vasopressors is noted if volume replacement proves insufficient. Furthermore, monitoring of renal function is a specified clinical requirement during the management of a Terazosin overdose.

Therapeutic Uses of Prostanorm

Prostanorm is applied in the management of two distinct, but often coexisting, chronic conditions. Its primary therapeutic domains and the symptoms it is used to manage primarily cover Benign Prostatic Hyperplasia (BPH) and Essential Hypertension.


Easing Obstructive Urinary Symptoms and Systemic Strain

Prostanorm is commonly used for the chronic management of BPH and the long-term support for managing elevated systemic blood pressure. In BPH, it specifically addresses the symptoms that interfere with daily functioning in adult men, such as a weak urine stream, urinary hesitancy, and the disruptive frequency, including nocturia. This therapeutic support contributes to easing the overall symptom load associated with prostate enlargement.

For hypertension, the medicine provides support that is relevant for easing persistent pressure and contributes to easing systemic strain. The medication is relevant in clinical scenarios where the patient may require dual management, meaning they present with both symptomatic BPH and coexisting hypertension.

“The support offered may assist in coping more steadily with difficult episodes, whether they are disruptive urinary issues or chronic high blood pressure.”


Quick Fact: Relief for Obstructive Symptoms
Symptom Category Obstructive and irritative symptoms of the lower urinary tract.
Typical Use Chronic management of BPH.
Key Benefit Contributes to maintaining functional stability.
Context Applied when BPH coexists with essential hypertension.

Regulatory References

  1. NIH MedlinePlus overview of Terazosin

Eligibility and Restrictions for Use

Who can and cannot use Prostanorm?

The official eligibility profile for Prostanorm (Terazosin) is defined by regulatory guidelines that determine approved populations and exclusions.

Eligibility Scope Status
Populations for Use Adults (age ge 18 years) [1.3, 2.4]
Contraindicated Populations Patients with known hypersensitivity to Terazosin or any quinazoline-type alpha-blocker, or a history of micturition syncope [2.4].
Age-Related Rules Use is not recommended for pediatric patients as safety and efficacy have not been established [2.4]. Older adults require caution due to increased risk of postural hypotension [2.1].
Physiological/Condition Status Use is not recommended during pregnancy or lactation unless the clinical benefit is judged to outweigh the potential risk [3.1, 3.2]. Hepatic dysfunction requires special caution [2.2].

The medicine is limited to the adult population and is strictly prohibited for individuals with specific allergies or a history of fainting associated with urination. Additionally, regulatory documents require prostatic cancer be excluded before treatment begins for BPH symptoms [2.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following table summarizes the officially documented interaction patterns for Prostanorm (Terazosin), as specified in government regulatory information. These interactions primarily fall into pharmacodynamic effects (additive blood pressure lowering) and pharmacokinetic changes (altered exposure).

Interaction Category Documented Interacting Substances and Outcomes
Additive Hypotensive Effects Co-administration with other antihypertensive agents (e.g., Diuretics, Beta-Blockers, Calcium Antagonists) may result in significant hypotension due to additive effects. PDE5 Inhibitors (like Sildenafil) also pose a risk of symptomatic low blood pressure. Non-Steroidal Antirheumatics (NSAIDs) may reduce the medicine's blood pressure-lowering efficacy.
Exposure Modification Co-administration with Verapamil has been formally documented to increase the systemic exposure of Terazosin (AUC and Cmax). Captopril does not significantly influence the plasma concentration of Terazosin.
Regulatory Restrictions Combination with other quinazoline-derived alpha-receptor blockers is officially not recommended due to the potential for excessive alpha-blocking effects. The concomitant use of substantial amounts of Alcohol may also increase the risk of hypotension.
Population Caution Use in patients with severe hepatic dysfunction is not recommended due to the lack of available data and the drug’s metabolism in the liver.

This profile is based strictly on the label-based interaction information, documenting specific prohibitions, cautions, and quantified changes in exposure as reported by official regulatory agencies.

Mechanism of Action

Prostanorm (Terazosin) exerts its action by engaging two primary mechanistic domains that lead to defined physiological changes in smooth muscle tone and resistance. Its effects are strictly based on interrupting sympathetic nervous system signals at the cellular level.

Alpha-1 Receptor Blockade and Signal Suppression

This domain covers the initial molecular interaction where the drug acts as a competitive antagonist by binding to the post-synaptic Alpha-1 (alpha1)-adrenergic receptors . By occupying these receptors, Prostanorm prevents their activation by the natural neurotransmitter Norepinephrine, effectively suppressing the signal that triggers smooth muscle contraction. This modification of the signaling sequence directly influences subsequent physiological responses.

Modulating Visceral and Vascular Smooth Muscle Tone

This domain addresses the cascading effect of signal suppression, focusing on the resulting tissue-level change. The blockade mechanism leads to the relaxation of smooth muscle primarily in the lower urinary tract and in the walls of blood vessels. This effect modulates the regulation of basal muscle tension, leading to a decrease in resistance and pressure throughout these affected systems.

Mechanistic Limitation to Dynamic Resistance

Prostanorm's action is confined to the dynamic component—the tension maintained by active muscle tone—and does not engage with biological pathways responsible for fixed tissue mass or volume. Therefore, the physiological change produced is a decrease in resistance resulting from muscle contraction, not structural enlargement.

Dosage and Administration Information

How to Use Prostanorm: Official Administration Guidelines

Prostanorm (Terazosin Hydrochloride) is an oral medication available in capsule, tablet, or solution form, following standardized administration procedures. The primary use principles are: mandatory bedtime dosing, gradual titration, and fixed rules for treatment interruption.


Standard Labeled Dosing Regimens (Adults)

Indication Initial Dose Maintenance Range Maximum Daily Dose
All Patients 1 mg once daily at bedtime (qHS) Titrated slowly 20 mg
BPH 1 mg qHS 2 mg to 10 mg once daily 20 mg
Hypertension 1 mg qHS 1 mg to 5 mg once daily 20 mg

Subsequent dose increases should be implemented in a stepwise fashion at weekly or bi-weekly intervals. For hypertension, a twice-daily regimen may be considered if the response is diminished at the 24-hour interval.


Key Administration Rules

  • Timing: The initial 1 mg dose, and all subsequent dose increases, must be administered at bedtime.
  • Food: The medication may be taken with or without food.
  • Re-initiation: If therapy is discontinued for several days or longer, treatment must be re-instituted using the initial 1 mg dose.
  • Population Adjustments: No alteration in the recommended dose is required for patients with renal impairment. However, the dose must be titrated with caution in patients with hepatic impairment due to the drug’s extensive metabolism.
  • Tablet Handling: For forms with a score line, this is only to facilitate swallowing; it must not be used to divide the dose into equal halves.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prostanorm

Evidence for Use in Symptomatic Benign Prostatic Hyperplasia (BPH)

This section summarizes the structure of the clinical evaluation for using Prostanorm to manage BPH symptoms, detailing the types of randomized controlled trials (RCTs) conducted, and the specific outcomes they measured, such as changes in urinary flow rate and symptom scores.

Prostanorm was evaluated in research exploring its use for people with symptomatic Benign Prostatic Hyperplasia (BPH). The main research came from Randomized Controlled Trials (RCTs) that compared the medicine against a placebo or other treatments, which examined short-term symptom changes in adult men with mild to moderate symptoms. Researchers examined patient-reported outcomes using standardized symptom scores. Studies also monitored objective functional measures, such as peak urinary flow rate (Q max) and post-void residual volume. Studies report patterns observed in the research, including measured changes in both symptom scores and functional measures. Follow-up durations were limited for many trials, and evidence remains limited regarding the role of the medicine in altering the long-term underlying course of BPH.


Evidence for Use in Essential Hypertension

This section describes the research base for Prostanorm's role in managing elevated systemic blood pressure. It outlines the nature of the clinical trials, including placebo-controlled and comparative studies, and specifies the blood pressure outcomes that were tracked.

Prostanorm was studied for Essential Hypertension, a condition representing outcomes related to systemic or functional imbalance. The research was conducted in adult patients with mild to moderate hypertension. The core objective of this research examined changes in blood pressure measurements. Studies monitored changes from the baseline level in both seated and standing systolic and diastolic blood pressure across the 24-hour dosing interval. Studies reported findings related to changes from baseline in blood pressure. Some trials also monitored changes in measured parameters related to cardiovascular health, and research described that measured blood pressure changes were negligible in non-hypertensive groups. Comparative evidence is lacking for long-term cardiovascular outcomes when stacked against other contemporary therapies.


Long-Term Studies and Follow-Up Data

Clinical evaluation has included short-term efficacy trials and longer open-label follow-up studies. Long-term open-label follow-up studies followed patients for several years. These studies show how symptoms evolved for extended periods. The evidence for the drug's effect on long-term clinical outcomes is limited, and certainty remains low regarding whether the medication alters the progression of BPH or hypertension over a patient’s lifetime.


What Is Still Uncertain About Prostanorm Research

While extensive research describes the measured short-term changes associated with Prostanorm, several areas of uncertainty remain. Long-term effects are not fully established, particularly the sustained impact on BPH progression. Subgroup findings are uncertain, as main studies were observed in broad populations, and sample sizes were modest for highly specific patient groups. The evidence quality varies across studies, and much of the longest-term data comes from open-label research, which has inherent limitations compared to blinded trials.

Key Studies & References

  1. Terazosin: MedlinePlus Drug Information (Uses, Side Effects, Interactions)
  2. Terazosin: MedlinePlus Drug Information (BPH and Hypertension Uses)

Frequently Asked Questions (FAQ)

Common questions about Prostanorm (FAQ)


Q: Is Prostanorm safe to take long-term?

A: Official information documents the results of long-term open-label follow-up studies that observed patients using the medication for several years. However, evidence remains limited regarding whether the medication alters the long-term underlying course of the conditions it treats.


Q: Can alcohol consumption interfere with Prostanorm's effect?

A: Yes, official warnings describe that combining Prostanorm with substantial amounts of alcohol may increase the risk of symptomatic hypotension. Hypotension is the medical term for low blood pressure.


Q: What happens if I stop taking Prostanorm suddenly?

A: If the medicine is stopped for several days or more, official instructions state that treatment must be re-instituted at the initial lowest dose. The regulatory instruction to restart at the initial dose helps manage the documented risk of first-dose-related low blood pressure (hypotension).


Q: What happens in the body when Prostanorm is working?

A: Prostanorm is an alpha-blocker that works by blocking specific nerve signals in the body. This action causes smooth muscles in the lower urinary tract and in blood vessel walls to relax. The result is a reduction in pressure and resistance within these systems.


Q: Does Prostanorm cause weight gain or loss?

A: Official trial data lists weight gain as an uncommon adverse reaction, reported in a small percentage of patients during studies. This change is not listed as one of the most frequently observed side effects.


Q: Can Prostanorm cause fatigue or tiredness?

A: Yes, official safety information lists asthenia as a very common side effect. Asthenia is the medical term for weakness or lack of energy, which is often described by patients as feeling tired or fatigued.


Q: Are the side effects of Prostanorm generally mild?

A: The official safety profile documents both common, less severe events like dizziness and weakness, and specific serious events like syncope (fainting) that are documented risks. It does not use the general term 'mild' or 'severe' to describe the overall profile.


Q: Is it normal to feel a change in sexual function while taking Prostanorm?

A: Official regulatory documents list impotence as a common side effect of Prostanorm. Additionally, post-marketing reports have included other events related to the reproductive system, such as priapism (a prolonged, painful erection).


Q: Can Prostanorm affect blood pressure?

A: Prostanorm is indicated for the treatment of hypertension (elevated blood pressure). However, its action can also cause postural hypotension, which is a common documented side effect. Postural hypotension is a temporary drop in blood pressure that occurs when standing up.


Q: Do I need to change my diet while on Prostanorm?

A: Official instructions state the medication can be taken with or without food. No specific or routine dietary changes are described in the regulatory documents for this medication.


Q: How long does it usually take to notice an effect from Prostanorm?

A: Research evidence suggests that patients with Benign Prostatic Hyperplasia (BPH) may begin to notice symptom changes within 2 to 4 weeks after starting the medication. Achieving the expected clinical effect can vary among individuals and may require continued use.


Q: What should I do if I miss a scheduled dose of Prostanorm?

A: Official patient information describes the general guidance for managing a missed dose. If a dose is missed, it is generally taken as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.


Q: Is Prostanorm suitable for all age groups with prostate issues?

A: Official guidelines limit the use of the medicine to adults (age 18 and older). Caution is specifically advised when used in older adults due to an increased risk of low blood pressure events in this population.


Q: Does the evidence for Prostanorm show a reduction in symptoms over time?

A: Clinical research reports improvements in patient-reported symptom scores and objective functional measures, such as peak urinary flow rates, compared to a placebo. This suggests a pattern of symptom reduction was observed.


Q: What are the general expectations about symptom improvement with Prostanorm?

A: Research evidence reports patterns of improvement in patient-reported Benign Prostatic Hyperplasia (BPH) symptom scores. These findings indicate that a reduction in the severity of symptoms is generally observed in clinical trials.


Q: Is Prostanorm known by any other brand names?

A: The active ingredient in Prostanorm is Terazosin. This ingredient has been marketed under other brand names, such as Hytrin, at various times and in different regions.


Q: Can I take Prostanorm before surgery?

A: Regulatory guidance specifically states that patients must inform their eye surgeon of current or past use of Prostanorm before undergoing cataract surgery. This caution is related to a documented risk of a complication known as Intraoperative Floppy Iris Syndrome (IFIS).


Q: What are the signs that Prostanorm may not be working for me?

A: If the expected symptom relief for BPH or consistent blood pressure control for hypertension is not observed, the medication's intended purpose may not be achieved. Lack of expected outcome is the primary indicator.


Q: Is there a generic version of Prostanorm available?

A: Yes, the active ingredient in Prostanorm is Terazosin. Terazosin is widely available as a generic medicine in the United States and other regions, often offering a lower-cost option.


Q: Does Prostanorm cause dry mouth?

A: In addition to the common side effects listed in the primary regulatory documents, some patients have reported experiencing dry mouth. It is not listed as one of the most frequently observed effects.


Q: Can Prostanorm cause dizziness?

A: Yes, official safety information lists dizziness as a very common side effect in clinical trials. This effect is often observed after the very first dose or when the dose is increased.


Q: What is the shelf life of Prostanorm?

A: The regulatory stability profile typically supports an expiration date (shelf life) of at least two years from the date of manufacture. The medication remains effective until that date, provided the required storage conditions are strictly met.


Q: Are there any known long-term side effects of Prostanorm?

A: Most documented side effects are observed during short-term use. However, rare events like priapism (prolonged erection) and severe allergic reactions have been reported through the postmarketing surveillance of widespread, long-term use.


Q: Is Prostanorm addictive?

A: No, Prostanorm (Terazosin) is not classified by the US Food and Drug Administration (FDA) or other major regulatory bodies as a controlled substance. Medications classified as controlled substances are those with potential for dependence or abuse.


Q: Does Prostanorm need to be taken at a specific time of day?

A: Yes, regulatory instructions mandate that the initial dose and all subsequent dose increases must be administered at bedtime. This specific timing is required to help mitigate the risk of experiencing first-dose low blood pressure (hypotension).


Q: Can I drive while taking Prostanorm?

A: Due to the common risk of dizziness and drowsiness, official instructions describe that patients must avoid driving a car, operating machinery, or performing dangerous tasks for 12 hours after the first dose or any dose increase, until they know how the medication affects them.


Q: What level of research evidence exists for Prostanorm?

A: The initial effectiveness and safety evidence for Prostanorm were derived from Randomized Controlled Trials (RCTs). This type of study is considered a high and reliable standard of clinical research.


Q: Is Prostanorm a hormone therapy?

A: No, Prostanorm is classified as an alpha-blocker (selective alpha1-adrenergic antagonist). It is a synthetic drug that works by blocking nerve signals and is not a hormone therapy.


Q: Do any official sources mention specific lifestyle changes alongside Prostanorm?

A: While the drug itself has no specific requirements for lifestyle changes, official guidelines for managing the conditions it treats (like hypertension) often recommend general lifestyle modifications. These may include diet, exercise, and blood pressure monitoring.

How should Prostanorm be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Prostanorm (Terazosin Hydrochloride) are mandatory requirements defined by regulatory labeling to maintain product integrity and ensure public safety.

Storage Component Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Must be protected from light and excess moisture.
Container Keep the medication in the original container and ensure it is tightly closed.
Child Safety Store securely out of the sight and reach of children.
Disposal Dispose of unused or expired product according to local regulations. Do not release into the environment, sewers, or wastewater.

These conditions are required to maintain the stability of the medication up to its labeled expiration date. Compliance with local regulations is necessary when discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostanorm found in:

A-Z Index: